The effect of treatment with montelukast on levels of serum interleukin-10, eosinophil cationic protein, blood eosinophil counts, and clinical parameters in children with asthma

Turkish Journal of Pediatrics

Volumn 51, Issue 5, 2009, Pages 460-465

  Yüksel, Birol ^a   Aydemir, Cumhur ^a   Üstündaǧ, Gonca ^a   Eldeş, Nilüfer ^a   Kutsal, Ebru ^a   Can, Murat ^a   Demirtaş, Selda ^b   Tomaç, Nazan ^c  

^a Zonguldak Karaelmas Universitesi Tip Fakultesi   (Turkey)

^b UFUK UNIVERSITY   (Turkey)

^c BASKENT UNIVERSITY   (Turkey)

Author keywords

Childhood asthma; Eosinophil; Interleukin 10; Montelukast

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; INTERLEUKIN 10; MONTELUKAST; SALBUTAMOL;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MALE; PEAK EXPIRATORY FLOW; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; SCHOOL CHILD; SCORING SYSTEM; TREATMENT DURATION;

ACETATES; ADOLESCENT; ANTI-ASTHMATIC AGENTS; ASTHMA; CASE-CONTROL STUDIES; CHILD; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHILS; FEMALE; HUMANS; INTERLEUKIN-10; LEUKOCYTE COUNT; LEUKOTRIENE ANTAGONISTS; MALE; QUINOLINES; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 76149145358     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. In: NIH Publication No. 97-4051. Bethesda (MD): National Institutes of Health; 1997.
2. Macfarlane AJ, Dworski R, Sheller JR, et al. Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics. Am J Respir Crit Care Med 2000; 161: 1553-1558.
3. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 2004; 173: 1503-1510.
4. Bisgaard H. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy 2001; 56 (Suppl): 7-11.
5. Smith LJ. Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents. Arch Intern Med 1996; 156: 2181-2189.
6. Bandeira-Melo C, Weller PF. Eosinophils and cysteinyl leukotrienes. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 135-143.
7. 1 >75%. Curr Med Res Opin 2004; 20: 1651-1659.
8. Melo RE, Sole D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses. J Allergy Clin Immunol 2003; 111: 301-307.
9. Wu K, Bi Y, Sun K, Wang C. IL-10-producing type 1 regulatory T cells and allergy. Cell Mol Immunol 2007; 4: 269-275.
10. Cottrez F, Hurst SD, Coffman RL, Groux H. T regulatory cells 1 inhibit a Th2-specific response in vivo. J Immunol 2000; 165: 4848-4853.
11. Heaton T, Rowe J, Turner S, et al. An immuno-epidemiological approach to asthma: identification of in vitro T-cell response patterns associated with different wheezing phenotypes in children. Lancet 2005; 365: 142-149.
12. Moore KW, Malefyt RW, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Ann Rev Immunol 2001; 19: 683-765.
13. Enk AH, Saloga J, Becker D, Mohamadzadeh M, Knop J. Induction of hapten-specific tolerance by interleukin 10 in vivo. J Exp Med 1994; 179: 1397-1402.
14. Warner JO, Naspitz CK. Third International Pediatric Consensus statement on the management of childhood asthma. International Pediatric Asthma Consensus Group. Pediatr Pulmonol 1998; 25: 1-17.
15. Juniper EF, Guyatt GH, Feeny DH, et al. Measuring quality of life in children with asthma. Qual Life Res 1996; 5: 35-46.
16. Santanello NC, Barber BL, Reiss TF, et al. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 1997; 10: 646-651.
17. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. National Institutes of Health (NIH) Publication 02-3659, Issued January 1995 (Institute Revised 2002). Available from: http://www.ginaasthma.com
18. Diamant Z, Grootendorst DC, Veselic-Charvat M, et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 1999; 29: 42-51.
19. Pizzichini E, Leff JA, Reiss TF, et al. Montelukast reduces airway eosinophilic inflammation in asthma. A randomized, controlled trial. Eur Respir J 1999; 14: 12-18.
20. Stelmach I, Majak P, Jerzynska J, Kuna P. The effect of treatment with montelukast on in vitro interleukin-10 production of mononuclear cells of children with asthma. Clin Exp Allergy 2005; 35: 213-220.
21. Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and β-agonist treatment on IL-10 serum levels in children with asthma. Clin Exp Allergy 2002; 32: 264-269.
22. Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma. J Allergy Clin Immunol 2002; 109: 257-263.
23. Borish L, Aarons A, Rumbyrt J, et al. Interleukin-10 regulation in normal and asthmatic subjects. J Allergy Clin Immunol 1996; 97: 1288-1296.
24. Hodge S, Hodge G, Flower R, Han P. Methylprednisolone up-regulates monocyte interleukin-10 production in stimulated whole blood. Scand J Immunol 1999; 49: 548-553.
25. John M, Lim S, Seybold J, et al. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein 1 alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med 1998; 157: 256-262.
26. Knorr B, Matz J, Bernstein A, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. JAMA 1998; 279: 1181-1186.